Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Arcutis Biotherapeutics (ARQT) FCF Margin (2022 - 2025)

Arcutis Biotherapeutics (ARQT) has 4 years of FCF Margin data on record, last reported at 19.91% in Q4 2025.

  • For Q4 2025, FCF Margin rose 2099.0% year-over-year to 19.91%; the TTM value through Dec 2025 reached 1.68%, up 6575.0%, while the annual FY2025 figure was 1.68%, 6575.0% up from the prior year.
  • FCF Margin reached 19.91% in Q4 2025 per ARQT's latest filing, up from 1.77% in the prior quarter.
  • Across five years, FCF Margin topped out at 19.91% in Q4 2025 and bottomed at 9338.07% in Q3 2022.
  • Average FCF Margin over 4 years is 1214.16%, with a median of 146.37% recorded in 2024.
  • Peak YoY movement for FCF Margin: surged 919124bps in 2023, then soared 2099bps in 2025.
  • A 4-year view of FCF Margin shows it stood at 2404.19% in 2022, then skyrocketed by 83bps to 415.87% in 2023, then skyrocketed by 100bps to 1.08% in 2024, then surged by 1946bps to 19.91% in 2025.
  • Per Business Quant database, its latest 3 readings for FCF Margin were 19.91% in Q4 2025, 1.77% in Q3 2025, and 0.3% in Q2 2025.